{"id":40486,"date":"2003-06-01T12:01:00","date_gmt":"2003-06-01T10:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2003\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie"},"modified":"2003-06-01T12:01:00","modified_gmt":"2003-06-01T10:01:00","slug":"lipidsenker-bei-hypertonikern-die-ascot-lla-studie","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie\/","title":{"rendered":"Lipidsenker bei Hypertonikern: Die ASCOT-LLA-Studie"},"content":{"rendered":"<p>Da Statine zu den meist verordneten und die Gesundheits-Budgets vieler L\u00e4nder am meisten belastenden Medikamenten geh\u00f6ren, sind neue gut durchgef\u00fchrte Studien an spezifischen Patientenkollektiven sehr willkommen. Da fast alle diese Studien von den das jeweilige Statin herstellenden oder vermarktenden Firmen gesponsert werden, besteht deren Motivation f\u00fcr das Sponsoring nat\u00fcrlich prinzipiell in dem Wunsch, die Indikationen [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Da Statine zu den meist verordneten und die Gesundheits-Budgets vieler L\u00e4nder am meisten belastenden Medikamenten geh\u00f6ren, sind neue gut durchgef\u00fchrte Studien an spezifischen Patientenkollektiven sehr willkommen. Da fast alle diese Studien von den das jeweilige Statin herstellenden oder vermarktenden Firmen gesponsert werden, besteht deren Motivation f\u00fcr das Sponsoring nat\u00fcrlich prinzipiell in dem Wunsch, die Indikationen [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[3988,67,4148,235,949,109,110,78,330,61,111,238,362,79,112,74,6023,242,60,113],"class_list":["post-40486","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-allhat-llt-studie","tag-apoplektischer-insult","tag-ascot-lla-studie","tag-atorvastatin","tag-blutdruck","tag-cholesterinsynthese-hemmer","tag-cse-hemmer","tag-herzinfarkt","tag-herzinsuffizienz","tag-hirninfarkt","tag-hmg-coa-reduktase-hemmer","tag-hypercholesterinaemie","tag-hypertonie","tag-koronare-herzkrankheit","tag-lipidsenker","tag-myokardinfarkt","tag-number-needed-to-treat","tag-pravastatin","tag-schlaganfall","tag-statine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lipidsenker bei Hypertonikern: Die ASCOT-LLA-Studie - Der Arzneimittelbrief<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lipidsenker bei Hypertonikern: Die ASCOT-LLA-Studie - Der Arzneimittelbrief\" \/>\n<meta property=\"og:description\" content=\"Da Statine zu den meist verordneten und die Gesundheits-Budgets vieler L\u00e4nder am meisten belastenden Medikamenten geh\u00f6ren, sind neue gut durchgef\u00fchrte Studien an spezifischen Patientenkollektiven sehr willkommen. Da fast alle diese Studien von den das jeweilige Statin herstellenden oder vermarktenden Firmen gesponsert werden, besteht deren Motivation f\u00fcr das Sponsoring nat\u00fcrlich prinzipiell in dem Wunsch, die Indikationen [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2003-06-01T10:01:00+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2012\/06\/logo_amb_neu.jpg\" \/>\n<meta name=\"author\" content=\"Dennis Hoppe\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dennis Hoppe\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie\\\/\"},\"author\":{\"name\":\"Dennis Hoppe\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"headline\":\"Lipidsenker bei Hypertonikern: Die ASCOT-LLA-Studie\",\"datePublished\":\"2003-06-01T10:01:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie\\\/\"},\"wordCount\":663,\"keywords\":[\"ALLHAT-LLT-Studie\",\"Apoplektischer Insult\",\"ASCOT-LLA-Studie\",\"Atorvastatin\",\"Blutdruck\",\"Cholesterinsynthese-Hemmer\",\"CSE-Hemmer\",\"Herzinfarkt\",\"Herzinsuffizienz\",\"Hirninfarkt\",\"HMG-CoA-Reduktase-Hemmer\",\"Hypercholesterin\u00e4mie\",\"Hypertonie\",\"Koronare Herzkrankheit\",\"Lipidsenker\",\"Myokardinfarkt\",\"Number needed to treat\",\"Pravastatin\",\"Schlaganfall\",\"Statine\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie\\\/\",\"name\":\"Lipidsenker bei Hypertonikern: Die ASCOT-LLA-Studie - Der Arzneimittelbrief\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"datePublished\":\"2003-06-01T10:01:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lipidsenker bei Hypertonikern: Die ASCOT-LLA-Studie\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a04aadd6db7c06c7464bdbbb5396ed16\",\"name\":\"Dennis Hoppe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g\",\"caption\":\"Dennis Hoppe\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lipidsenker bei Hypertonikern: Die ASCOT-LLA-Studie - Der Arzneimittelbrief","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie\/","og_locale":"de_DE","og_type":"article","og_title":"Lipidsenker bei Hypertonikern: Die ASCOT-LLA-Studie - Der Arzneimittelbrief","og_description":"Da Statine zu den meist verordneten und die Gesundheits-Budgets vieler L\u00e4nder am meisten belastenden Medikamenten geh\u00f6ren, sind neue gut durchgef\u00fchrte Studien an spezifischen Patientenkollektiven sehr willkommen. Da fast alle diese Studien von den das jeweilige Statin herstellenden oder vermarktenden Firmen gesponsert werden, besteht deren Motivation f\u00fcr das Sponsoring nat\u00fcrlich prinzipiell in dem Wunsch, die Indikationen [&hellip;]","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2003-06-01T10:01:00+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2012\/06\/logo_amb_neu.jpg","type":"","width":"","height":""}],"author":"Dennis Hoppe","twitter_misc":{"Verfasst von":"Dennis Hoppe","Gesch\u00e4tzte Lesezeit":"3\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie\/"},"author":{"name":"Dennis Hoppe","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"headline":"Lipidsenker bei Hypertonikern: Die ASCOT-LLA-Studie","datePublished":"2003-06-01T10:01:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie\/"},"wordCount":663,"keywords":["ALLHAT-LLT-Studie","Apoplektischer Insult","ASCOT-LLA-Studie","Atorvastatin","Blutdruck","Cholesterinsynthese-Hemmer","CSE-Hemmer","Herzinfarkt","Herzinsuffizienz","Hirninfarkt","HMG-CoA-Reduktase-Hemmer","Hypercholesterin\u00e4mie","Hypertonie","Koronare Herzkrankheit","Lipidsenker","Myokardinfarkt","Number needed to treat","Pravastatin","Schlaganfall","Statine"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie\/","name":"Lipidsenker bei Hypertonikern: Die ASCOT-LLA-Studie - Der Arzneimittelbrief","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"datePublished":"2003-06-01T10:01:00+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16"},"breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/lipidsenker-bei-hypertonikern-die-ascot-lla-studie\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Lipidsenker bei Hypertonikern: Die ASCOT-LLA-Studie"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a04aadd6db7c06c7464bdbbb5396ed16","name":"Dennis Hoppe","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bfb16656c0e1636d4f543ef457ada76f291324632a293160dd5c869cc3b071d7?s=96&d=mm&r=g","caption":"Dennis Hoppe"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40486","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=40486"}],"version-history":[{"count":0,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/40486\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=40486"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=40486"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=40486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}